Endogenous and synthetic MMP inhibitors in CNS physiopathology - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Progress in Brain Research Année : 2014

Endogenous and synthetic MMP inhibitors in CNS physiopathology

Kévin Baranger
  • Fonction : Auteur
Fabian D. Liechti
  • Fonction : Auteur
Denis Grandgirard
  • Fonction : Auteur
Judit Bigas
  • Fonction : Auteur
Jesús Seco
  • Fonction : Auteur
Teresa Tarrago
  • Fonction : Auteur
Stephen L. Leib
  • Fonction : Auteur

Résumé

Matrix metalloproteinases (MMPs, including the membrane-type MMPs (MT-MMPs)), a disintegrin and metalloproteinase (ADAM), and ADAM with thrombospondin motifs belong to the metzincins, a subclass of metalloproteinases that contain a Met residue and a Zn(2+) ion at the catalytic site necessary for enzymatic reaction. MMP proteolytic activity is mainly controlled by their natural tissue inhibitors of metalloproteinase (TIMP). A number of synthetic inhibitors have been developed to control deleterious MMP activity. The roles of MMPs and some of their ECM substrates in CNS physiology and pathology are covered by other chapters of the present volume and will thus not be addressed in depth. This chapter will focus (i) on the endogenous MMP inhibitors in the CNS, (ii) on MMP and TIMP regulations in three large classes of neuropathologic processes (inflammatory, neurodegenerative, and infectious), and (iii) on synthetic inhibitors of MMPs and the perspective of their use in different brain diseases.
Fichier non déposé

Dates et versions

hal-01718187 , version 1 (27-02-2018)

Identifiants

Citer

Kévin Baranger, Santiago Rivera, Fabian D. Liechti, Denis Grandgirard, Judit Bigas, et al.. Endogenous and synthetic MMP inhibitors in CNS physiopathology. Progress in Brain Research, 2014, 214, pp.313--351. ⟨10.1016/B978-0-444-63486-3.00014-1⟩. ⟨hal-01718187⟩
114 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More